OncoMatch/Clinical Trials/NCT04952480
Dose-escalated Adaptive Radiotherapy of Thoracic Disease for Small Cell Lung Cancer
Is NCT04952480 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Chemotherapy for small cell lung cancer.
Treatment: Chemotherapy — The purpose of this study is to find out what effects of using adaptive radiotherapy to deliver chest radiation has on the ability to control lung cancer and side effects.
Check if I qualifyExtracted eligibility criteria
Cancer type
Small Cell Lung Cancer
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: CNS or thoracic radiotherapy
Previous CNS or thoracic radiotherapy
Cannot have received: chemotherapy
Previous chemotherapy
Cannot have received: thoracic surgery
Prior thoracic surgery
Lab requirements
Kidney function
Kidney disease with irreversibly low creatinine clearance inadequate for IV contrast administration excluded
kidney disease with irreversibly low creatinine clearance inadequate for IV contrast administration (for the purposes of high quality contrast enhanced CT chest and abdomen for follow-up imaging)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify